OncoMatch/Clinical Trials/NCT05284552
Tinzaparin And Biomarkers After Neoadjuvant Treatment of Ovarian Cancer
Is NCT05284552 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Tinzaparin Injectable Solution for epithelial ovarian cancer.
Treatment: Tinzaparin Injectable Solution — Background: Previous findings have indicated antineoplastic properties of tinzaparin (Innohep®), a commonly used anti-coagulant. Earlier studies have mainly investigated the antineoplastic effects of tinzaparin in animal models and in human cell-lines. In this pilot study the aim is to examine the potential antitumoral effects of tinzaparin in vivo in women with epithelial ovarian cancer (EOC). Study objectives: Primary objective: The primary objective of the study is to evaluate the effects of tinzaparin on changes in levels of CA-125 in EOC patients who receive neoadjuvant chemotherapy (NACT). Secondary objectives: The secondary objective of the study is to explore the impact of tinzaparin on the dynamic of a spectrum of immunological and coagulation factors in EOC patients who receive NACT. Besides, the compliance of tinzaparin injections and adverse events caused by tinzaparin will be described.
Check if I qualifyExtracted eligibility criteria
Cancer type
Ovarian Cancer
Disease stage
Required: Stage FIGO III, FIGO IV (FIGO)
Grade: high grade serous carcinoma
FIGO stage III-IV disease. Histology diagnosis of either high grade serous carcinoma, endometrioid carcinoma or clear cell carcinoma.
Performance status
WHO 0–1
Prior therapy
Cannot have received: heparin
Concomitant treatment with heparins, low molecular weight heparins, warfarin or nonvitamin K antagonist oral anticoagulants. Platelet inhibitors are allowed.
Cannot have received: heparin
Treatment with heparins, low molecular weight heparins or non-vitamin K antagonist oral anticoagulants within the last year.
Cannot have received: platinum single regimen
Platinum single regimen
Cannot have received: treatment for other known malignancy
Exception: except basal cell carcinoma
Treatment for other known malignancy within the last year (except basal cell carcinoma)
Lab requirements
Blood counts
Platelets <100 x10^9/L (analyzed no more than 14 days before start of treatment with investigational product) [excluded]
Kidney function
Estimated glomerular filtration rate (E-GFR) <30ml/min (analyzed no more than 14 days before start of treatment with investigational product) [excluded]
Estimated glomerular filtration rate (E-GFR) <30ml/min (analyzed no more than 14 days before start of treatment with investigational product); Platelets <100 x10^9/L (analyzed no more than 14 days before start of treatment with investigational product)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify